Evaluation

University of Phoenix College of Doctoral Studies New Edition of Its Phoenix ScholarTM Academic Journal Highlights Education Innovation at the University

Retrieved on: 
Friday, September 23, 2022

University of Phoenix has released the 15th edition of the Phoenix Scholar academic research journal with a special issue dedicated to showcasing the singular focus of work being done as the preeminent university serving working adults.

Key Points: 
  • University of Phoenix has released the 15th edition of the Phoenix Scholar academic research journal with a special issue dedicated to showcasing the singular focus of work being done as the preeminent university serving working adults.
  • The articles in this journal span research conducted by faculty, academic administration, and the Universitys Research Centers, as well as theory-based research that drives continuous quality improvement across the Universitys administrative units.
  • The research pieces collected for this special issue of Phoenix Scholar represent a sample of the innovation at a university that has emerged from the days of COVID-19 stronger than it entered.
  • The Phoenix Scholar journal is the academic research publication of University Phoenixs College of Doctoral Studies and serves as the scholarly platform for communicating the results and outcomes of university research endeavors, and their relationship to the broader scope of learning and scholarship.

BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY

Retrieved on: 
Thursday, September 22, 2022

Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.

Key Points: 
  • Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.
  • This challenge will require the submission of a written proposal directly via the Wazoku Platform before October 15th, 2022.
  • ADCs are large and complex molecules composed of an antibody, with two Fab and a Fc, linked to a biologically active cytotoxic payload.
  • Through this Challenge, Debiopharm hopes to develop new non-invasive diagnostic methods and to improve the specificity of Drug Targeting to best preserve healthy tissue.

BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY

Retrieved on: 
Thursday, September 22, 2022

Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.

Key Points: 
  • Through Wazoku, an open innovation crowdsourcing platform, the Challenge has been launched globally to participants from various backgrounds, including science, engineering, and technology.
  • This challenge will require the submission of a written proposal directly via the Wazoku Platform before October 15th, 2022.
  • ADCs are large and complex molecules composed of an antibody, with two Fab and a Fc, linked to a biologically active cytotoxic payload.
  • Through this Challenge, Debiopharm hopes to develop new non-invasive diagnostic methods and to improve the specificity of Drug Targeting to best preserve healthy tissue.

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

Retrieved on: 
Tuesday, September 20, 2022

(Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced positive safety, tolerability and efficacy results from its recent analysis of the Companys ongoing STS101 ASCEND Phase 3 open-label, long-term safety trial.

Key Points: 
  • (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced positive safety, tolerability and efficacy results from its recent analysis of the Companys ongoing STS101 ASCEND Phase 3 open-label, long-term safety trial.
  • The STS101 ASCEND Phase 3 long-term safety trial is a multi-center, open-label trial in subjects with migraine that is being conducted in the United States.
  • For further information regarding the STS101 ASCEND Phase 3 long-term safety trial, see www.ClinicalTrials.gov, identifier NCT04406649: A Study to Evaluate STS101 in the Acute Treatment of Migraine (ASCEND).
  • No representation is made as to the safety or effectiveness of STS101 for the therapeutic use for which STS101 is being studied.

Outdated Employee Value Propositions Linked to 22% Decline in HR Recruiting Effectiveness, Says HR Research Firm McLean & Company

Retrieved on: 
Wednesday, September 14, 2022

"Talent attraction and retention challenges exist for all organizations, whether onsite, remote, or hybrid," says Laura Ribadeneira , director, HR Research & Advisory Services at McLean & Company.

Key Points: 
  • "Talent attraction and retention challenges exist for all organizations, whether onsite, remote, or hybrid," says Laura Ribadeneira , director, HR Research & Advisory Services at McLean & Company.
  • "In an effort to combat these obstacles, a realistic and compelling employee value proposition (EVP) should be created."
  • McLean & Company's blueprint explains that an up-to-date EVP provides a holistic view of the organization's strengths and offerings.
  • For more information about McLean & Company or to download the latest research, visit hr.mcleanco.com and connect via LinkedIn and Twitter .

Prodigy Technovations announces innovative PCIeGen3/4 Protocol Analyzer

Retrieved on: 
Wednesday, September 14, 2022

Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.

Key Points: 
  • Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.
  • PCIeGen3/4 Protocol Analyzer is used for development and validation of PCIe interface for M.2, U.2 and Embedded PCIe Bus.
  • PCIe Protocol Analyzer supports trigger on content of the protocol packets and if-then-elseif multi-level trigger capability.
  • Simultaneous Protocol analysis of 2.5, 5, 8, and 16GT/S Protocol Traffic
    Acquisition memory management to capture protocol traffic using trigger, segmented memory, circular buffer and hardware filters
    Simple and advanced Trigger based on TS1, TS2, DLLP and TLP Protocol packet content
    The PGY-PCIeGen3/4-PA , is now orderable.

Prodigy Technovations announces innovative PCIeGen3/4 Protocol Analyzer

Retrieved on: 
Wednesday, September 14, 2022

Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.

Key Points: 
  • Ltd , a Bangalore-based company, introduces its PGY-PCIeGen3/4-PA PCIe Protocol Analyzer supporting 2.5, 5.0.
  • PCIeGen3/4 Protocol Analyzer is used for development and validation of PCIe interface for M.2, U.2 and Embedded PCIe Bus.
  • PCIe Protocol Analyzer supports trigger on content of the protocol packets and if-then-elseif multi-level trigger capability.
  • Simultaneous Protocol analysis of 2.5, 5, 8, and 16GT/S Protocol Traffic
    Acquisition memory management to capture protocol traffic using trigger, segmented memory, circular buffer and hardware filters
    Simple and advanced Trigger based on TS1, TS2, DLLP and TLP Protocol packet content
    The PGY-PCIeGen3/4-PA , is now orderable.

RoviSys Announces Federal Solutions Business - Dedicated Automation & Information Solutions for the Federal Government

Retrieved on: 
Tuesday, September 13, 2022

AURORA, Ohio, Sept. 13, 2022 /PRNewswire-PRWeb/ -- RoviSys, a leading independent provider of comprehensive process automation, building automation, and discrete automation solutions announced today continued expansion of operations with the establishment of RoviSys Federal Solutions (RFS). RoviSys Federal Solutions is focused on providing automation and information solutions for challenges at the heart of the nation's priorities, including national security, cybersecurity, smart infrastructure, and healthcare and citizen services. RFS connects federal agencies with automation and security solutions that enable smart infrastructure, address evolving threats, and facilitate improved efficiency and resiliency, all while managing costs.

Key Points: 
  • AURORA, Ohio, Sept. 13, 2022 /PRNewswire-PRWeb/ -- RoviSys, a leading independent provider of comprehensive process automation, building automation, and discrete automation solutions announced today continued expansion of operations with the establishment of RoviSys Federal Solutions (RFS).
  • RoviSys Federal Solutions is focused on providing automation and information solutions for challenges at the heart of the nation's priorities, including national security, cybersecurity, smart infrastructure, and healthcare and citizen services.
  • "RoviSys Federal Solutions delivers cutting edge automation and information solutions, underpinned by our 33-year history in the industrial and building automation domains, to the federal government while being mindful of requirements for compliance, resiliency, and cybersecurity," said Graham Staples.
  • RoviSys is an independent systems integrator that provides process automation, building automation, and discrete manufacturing automation solutions.

Hussey Seating Company Successfully Completes ICC-ES Evaluation Report Process

Retrieved on: 
Tuesday, September 6, 2022

Hussey Seating Company, a global leader in designing and manufacturing spectator seating solutions, has received an Evaluation Report from the International Code Council Evaluation Service (ICC-ES) for its MAXAM, MAXAM+, and MXP telescopic seating systems.

Key Points: 
  • Hussey Seating Company, a global leader in designing and manufacturing spectator seating solutions, has received an Evaluation Report from the International Code Council Evaluation Service (ICC-ES) for its MAXAM, MAXAM+, and MXP telescopic seating systems.
  • In conjunction with this achievement, Hussey Seating Company has been granted Evaluation Report #ESR-5033.
  • As Hussey Seating Company continues to push the standards of safety and quality in spectator seating, we urge architects to also demand higher standards by specifying industry endorsements such as an ICC-ES Evaluation Report, American Welding Society Certification, Canadian Welding Bureau Certification, and the like, says Gary Merrill CEO of Hussey Seating Company.
  • Hussey Seating Company is the world leader in designing and manufacturing seating solutions for the sports and entertainment, education, esports and performing arts markets.

DuPont announces two updated fire listings for DuPont™ ArmorWall™ Systems through ICC-ES

Retrieved on: 
Wednesday, August 31, 2022

WILMINGTON, Del., Aug. 31, 2022 /PRNewswire-PRWeb/ -- DuPont Performance Building Solutions announced today their DuPont™ ArmorWall™ Systems received two updated fire listings from the International Code Council (ICC) – ICC-ESL-1302 applicable to ASTM E119 and ICC-ESL-1442 applicable to NFPA 285.

Key Points: 
  • WILMINGTON, Del., Aug. 31, 2022 /PRNewswire-PRWeb/ -- DuPont Performance Building Solutions announced today their DuPont ArmorWall Systems received two updated fire listings from the International Code Council (ICC) ICC-ESL-1302 applicable to ASTM E119 and ICC-ESL-1442 applicable to NFPA 285.
  • DuPont ArmorWall Systems are premium five-in-one systems incorporating five traditional building enclosure elements into a single panel product: structural sheathing, fire-resistance, air- and water-resistive barriers, and a high-performance continuous insulation layer.
  • ArmorWall Systems have undergone rigorous testing and allow projects to meet continuous insulation building codes and the tight timelines of construction schedules faster and more cost-effectively.
  • DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life.